Tech billionaire Peter Thiel backs a leading psychedelic drug developer
Right on the heels of investing in antibody drug developer AbCellera, Facebook billionaire Peter Thiel has jumped into a syndicate putting up $125 million for a company with a portfolio of psychedelic drugs in the clinic for mental health.
The C round — which includes a $32 million conversion of notes to equity — will fuel the development programs at ATAI Life Sciences, a Berlin-based biotech that has assembled a portfolio of companies with psychedelic and non-psychedilc approaches to depression, anxiety and addiction.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,600+ biopharma pros reading Endpoints daily — and it's free.